论文部分内容阅读
目的:探讨CD58/CD2在宫颈癌患者的表达水平及其与临床病理特征的关系。方法:分别应用免疫组织化学技术及流式细胞术检测40例宫颈癌患者及30例CIN患者组织CD58水平和外周血CD2+细胞百分率,以30例子宫肌瘤患者作为正常对照。结果:宫颈癌患者外周血CD2+细胞百分率及癌组织CD58表达水平均明显低于CIN组及正常对照组,差异均具有统计学意义(P<0.05),且不同病理分级、肿瘤直径及间质浸润深度宫颈癌患者CD2+细胞百分率和CD58表达水平分别比较,差异均具有统计学意义(P<0.05),而不同临床分期、年龄及绝经与否宫颈癌患者CD2+细胞百分率和CD58表达水平分别比较,差异均无统计学意义(P>0.05)。结论:CD58/CD2的表达与宫颈癌的发生、发展有关,二者可作为治疗及评价预后的参考指标,并可为肿瘤靶向治疗提供新靶点。
Objective: To investigate the expression of CD58 / CD2 in cervical cancer patients and its relationship with clinicopathological features. Methods: The levels of CD58 and percentage of CD2 + cells in peripheral blood of 40 cases of cervical cancer and 30 cases of CIN were detected by immunohistochemistry and flow cytometry respectively. Thirty cases of uterine fibroids were used as normal control. Results: The percentage of CD2 + cells and the expression of CD58 in peripheral blood of patients with cervical cancer were significantly lower than those in CIN and normal controls (P <0.05), and the differences in pathological grade, tumor diameter and interstitial infiltration The differences of CD2 + cell percentage and CD58 expression between patients with cervical cancer and those with advanced cervical cancer were statistically significant (P <0.05), but there was no difference between the different clinical stage, age, and the percentage of CD2 + cells and CD58 expression in patients with cervical cancer No statistical significance (P> 0.05). Conclusion: The expression of CD58 / CD2 is correlated with the occurrence and development of cervical cancer. Both of them may serve as reference indexes for the treatment and evaluation of prognosis, and may provide a new target for tumor targeted therapy.